热景生物股价跌5.12%，华夏基金旗下1只基金重仓，持有2.96万股浮亏损失28.63万元

Group 1 - The core point of the news is that Beijing Hotgen Biotech Co., Ltd. experienced a stock decline of 5.12%, with a current share price of 179.31 yuan and a total market capitalization of 16.623 billion yuan [1] - The company specializes in the research, development, production, and sales of in vitro diagnostic reagents and instruments, with its main revenue sources being testing reagents (70.87%), testing instruments (19.79%), other (8.17%), and biological raw materials (1.17%) [1] Group 2 - According to data, Huaxia Fund has a significant holding in Hotgen Biotech, with the Huaxia SSE STAR 200 ETF (588820) increasing its stake by 28,000 shares in the third quarter, bringing the total to 29,600 shares, which represents 1.06% of the fund's net value [2] - The Huaxia SSE STAR 200 ETF has a current scale of 476 million yuan and has achieved a year-to-date return of 14.98%, ranking 260 out of 5,525 in its category [2] - The fund manager of the Huaxia SSE STAR 200 ETF is Hualong, who has been in the position for 3 years and 148 days, with the best fund return during this period being 139.26% [3]